Publications
Publications
In review and/or preprint
In review and/or preprint
110. Comparative radiotracing reveals unique patterns of brain uptake and catabolism for bispecific antibodies targeting transferrin receptor and CD98hc, in review (2024).
110. Comparative radiotracing reveals unique patterns of brain uptake and catabolism for bispecific antibodies targeting transferrin receptor and CD98hc, in review (2024).
109. Design of medicine-like antibody libraries using deep learning, in review (2024).
109. Design of medicine-like antibody libraries using deep learning, in review (2024).
108. Maximizing activity and selectivity of antibody-mediated effector functions using antibody mixtures, in review (2024).
108. Maximizing activity and selectivity of antibody-mediated effector functions using antibody mixtures, in review (2024).
107. In vivo auto-tuning of antibody-drug conjugate delivery for effective immunotherapy using high-avidity, low-affinity antibodies, preprint (2024). [link]
107. In vivo auto-tuning of antibody-drug conjugate delivery for effective immunotherapy using high-avidity, low-affinity antibodies, preprint (2024). [link]
Published or in press
Published or in press
106. Flow cytometric isolation of drug-like conformational antibodies specific for amyloid fibrils, Nat Chem Biol, in press (2024). [link]
106. Flow cytometric isolation of drug-like conformational antibodies specific for amyloid fibrils, Nat Chem Biol, in press (2024). [link]
105. TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanisms, Cell Rep, in press (2024). [link]
105. TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanisms, Cell Rep, in press (2024). [link]
104. Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer’s disease samples, Biomat Sci (2024). [link]
104. Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer’s disease samples, Biomat Sci (2024). [link]
103. Ultra-dilute developability analysis of antibody self-association and non-specific binding, Methods Mol Biol, in press (2024).
103. Ultra-dilute developability analysis of antibody self-association and non-specific binding, Methods Mol Biol, in press (2024).
102. Human antibody polyreactivity is governed primarily by the heavy chain complementarity-determining regions, Cell Rep (2024). [link]
102. Human antibody polyreactivity is governed primarily by the heavy chain complementarity-determining regions, Cell Rep (2024). [link]
101. Monoclonal antibody generation using single B-cell screening for treating infectious diseases, BioDrugs (2024). [link]
101. Monoclonal antibody generation using single B-cell screening for treating infectious diseases, BioDrugs (2024). [link]
100. Native ion mobility-mass spectrometry reveals the binding mechanisms of anti-amyloid therapeutic antibodies, Protein Sci (2024). [link]
100. Native ion mobility-mass spectrometry reveals the binding mechanisms of anti-amyloid therapeutic antibodies, Protein Sci (2024). [link]
99. Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates, Biotechnol Prog (2024). [link]
99. Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates, Biotechnol Prog (2024). [link]
98. Reduction of monoclonal antibody viscosity using interpretable machine learning, mAbs (2024). [link]
98. Reduction of monoclonal antibody viscosity using interpretable machine learning, mAbs (2024). [link]
97. Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily, Cell Chem Biol (2024). [link]
97. Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily, Cell Chem Biol (2024). [link]
96. Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs, Cell Chem Biol (2024). [link] [news story]
96. Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs, Cell Chem Biol (2024). [link] [news story]
95. Quantitative flow cytometric selection of tau conformational nanobodies specific for pathological aggregates, Front Immunol (2023). [link]
95. Quantitative flow cytometric selection of tau conformational nanobodies specific for pathological aggregates, Front Immunol (2023). [link]
94. Optimization of therapeutic antibodies for reduced self-association and non-specific binding using interpretable machine learning, Nat Biomed Eng (2024). [link] [news story]
94. Optimization of therapeutic antibodies for reduced self-association and non-specific binding using interpretable machine learning, Nat Biomed Eng (2024). [link] [news story]
92. Position-Specific Enrichment Ratio Matrix scores predict antibody variant properties from deep sequencing data, Bioinformatics (2023). [link]
92. Position-Specific Enrichment Ratio Matrix scores predict antibody variant properties from deep sequencing data, Bioinformatics (2023). [link]
91. Computational optimization of antibody humanness and stability by systematic energy-based ranking, Nat Biomed Eng (2023). [link]
91. Computational optimization of antibody humanness and stability by systematic energy-based ranking, Nat Biomed Eng (2023). [link]
90. Characterization of pairs of toxic and nontoxic misfolded protein oligomers elucidates the structural determinants of oligomer toxicity in protein misfolding diseases, Acc Chem Res (2023). [link]
90. Characterization of pairs of toxic and nontoxic misfolded protein oligomers elucidates the structural determinants of oligomer toxicity in protein misfolding diseases, Acc Chem Res (2023). [link]
89. Assessing developability early in the discovery process for novel biologics, mAbs (2023). [link]
89. Assessing developability early in the discovery process for novel biologics, mAbs (2023). [link]
88. Approaches to expand the conventional toolbox for discovery and selection of drug-like antibodies, mAbs (2023). [link]
88. Approaches to expand the conventional toolbox for discovery and selection of drug-like antibodies, mAbs (2023). [link]
87. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering, Trends Mol Med (2023). [link]
87. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering, Trends Mol Med (2023). [link]
85. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning, mAbs (2022). [link] [press release]
85. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning, mAbs (2022). [link] [press release]
84. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space, Nat Commun (2022). [link] [blog] [press release]
84. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space, Nat Commun (2022). [link] [blog] [press release]
83. Mutational analysis of SARS-CoV-2 Variants of Concern reveals key tradeoffs between receptor affinity and antibody escape, PLOS Comput Biol (2022). [link]
83. Mutational analysis of SARS-CoV-2 Variants of Concern reveals key tradeoffs between receptor affinity and antibody escape, PLOS Comput Biol (2022). [link]
82. Isolating anti-amyloid antibodies from yeast-displayed libraries, Methods Mol Biol (2022). [link]
82. Isolating anti-amyloid antibodies from yeast-displayed libraries, Methods Mol Biol (2022). [link]
81. Rapid and quantitative in-vitro evaluation of SARS-CoV-2 neutralizing antibodies and nanobodies, Anal Chem (2022). [link]
81. Rapid and quantitative in-vitro evaluation of SARS-CoV-2 neutralizing antibodies and nanobodies, Anal Chem (2022). [link]
80. Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties, Mol Pharm (2022). [link]
80. Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties, Mol Pharm (2022). [link]
79. Facile isolation of high-affinity nanobodies from synthetic libraries using CDR-swapping mutagenesis, STAR Protoc (2022). [link]
79. Facile isolation of high-affinity nanobodies from synthetic libraries using CDR-swapping mutagenesis, STAR Protoc (2022). [link]
77. Agonist antibody discovery: experimental, computational and rational engineering approaches, Drug Discov Today (2022). [link]
77. Agonist antibody discovery: experimental, computational and rational engineering approaches, Drug Discov Today (2022). [link]
76. A hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain, PLoS One (2021). [link]
76. A hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain, PLoS One (2021). [link]
75. Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening, Sci Rep (2021). [link]
75. Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening, Sci Rep (2021). [link]
74. Systematic engineering of optimized autonomous heavy-chain variable domains, J Mol Biol (2021). [link]
74. Systematic engineering of optimized autonomous heavy-chain variable domains, J Mol Biol (2021). [link]
73. Engineered multivalent nanobodies potently and broadly neutralize SARS-CoV-2 variants, Adv Ther (2021). [link]
73. Engineered multivalent nanobodies potently and broadly neutralize SARS-CoV-2 variants, Adv Ther (2021). [link]
72. Highly sensitive detection of antibody non-specific interactions using flow cytometry, mAbs (2021). [link]
72. Highly sensitive detection of antibody non-specific interactions using flow cytometry, mAbs (2021). [link]
71. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods, mAbs (2021). [link]
71. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods, mAbs (2021). [link]
70. Ultra-dilute measurements of self-association for the identification of antibodies with favorable high concentration solution properties, Mol Pharm (2021). [link]
70. Ultra-dilute measurements of self-association for the identification of antibodies with favorable high concentration solution properties, Mol Pharm (2021). [link]
69. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis, Cell Chem Biol (2021). [link][news story]
69. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis, Cell Chem Biol (2021). [link][news story]
68. Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity, J Biol Chem (2021). [link]
68. Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity, J Biol Chem (2021). [link]
67. Directed evolution of conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic drug formulations, Biotech Biogen (2021). [link]
67. Directed evolution of conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic drug formulations, Biotech Biogen (2021). [link]
66. Toward in silico CMC: An industrial collaborative approach to model‐based process development, Biotech Biogen (2020). [link]
66. Toward in silico CMC: An industrial collaborative approach to model‐based process development, Biotech Biogen (2020). [link]
64. Physicochemical rules for identifying monoclonal antibodies with drug-like specificity, Mol Pharm (2020). [link]
64. Physicochemical rules for identifying monoclonal antibodies with drug-like specificity, Mol Pharm (2020). [link]
63. Directed evolution methods for overcoming trade-offs between protein activity and stability, AIChE Journal (special issue honoring Frances Arnold's Nobel Prize) (2020). [link]
63. Directed evolution methods for overcoming trade-offs between protein activity and stability, AIChE Journal (special issue honoring Frances Arnold's Nobel Prize) (2020). [link]
62. Unique impacts of methionine oxidation, tryptophan oxidation and asparagine deamidation on antibody stability and aggregation, J Pharm Sci (2020). [link]
62. Unique impacts of methionine oxidation, tryptophan oxidation and asparagine deamidation on antibody stability and aggregation, J Pharm Sci (2020). [link]
61. An engineered, pH-toggle switch, human Fc domain for ultra-long circulation persistence , Nat Commun (2019). [link]
61. An engineered, pH-toggle switch, human Fc domain for ultra-long circulation persistence , Nat Commun (2019). [link]
60. Sensitive detection of glucagon aggregation using amyloid fibril-specific antibodies, Biotech Bioeng, (2019). [link]
60. Sensitive detection of glucagon aggregation using amyloid fibril-specific antibodies, Biotech Bioeng, (2019). [link]
58. Deamidation compromises antibody colloidal stability and enhances aggregation in a pH-dependent manner, Mol Pharm (2019). [link]
58. Deamidation compromises antibody colloidal stability and enhances aggregation in a pH-dependent manner, Mol Pharm (2019). [link]
57. Selecting and engineering monoclonal antibodies with drug-like specificity, Current Opin Biotech (2019). [link]
57. Selecting and engineering monoclonal antibodies with drug-like specificity, Current Opin Biotech (2019). [link]
56. Net charge of the complementarity-determining regions is a key predictor of antibody specificity, Protein Eng Des Sel (2018). [link]
56. Net charge of the complementarity-determining regions is a key predictor of antibody specificity, Protein Eng Des Sel (2018). [link]
55. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility, Biochem Eng J (2018). [link]
55. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility, Biochem Eng J (2018). [link]
54. Biophysical and sequence-based methods for identifying monovalent and bivalent antibodies with high colloidal stability, Mol Pharm (2018). [link]
54. Biophysical and sequence-based methods for identifying monovalent and bivalent antibodies with high colloidal stability, Mol Pharm (2018). [link]
53. Facile affinity maturation of antibody variable domains using natural diversity mutagenesis, Front Immunol (2017). [link]
53. Facile affinity maturation of antibody variable domains using natural diversity mutagenesis, Front Immunol (2017). [link]
52. Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs, J Biol Chem (2017). [link]
52. Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs, J Biol Chem (2017). [link]
51. Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability, Sci Rep (2017). [link]
51. Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability, Sci Rep (2017). [link]
48. Facile preparation of stable antibody-gold conjugates and application to affinity-capture self-interaction nanoparticle spectroscopy, Bioconjug Chem (2016). [link]
48. Facile preparation of stable antibody-gold conjugates and application to affinity-capture self-interaction nanoparticle spectroscopy, Bioconjug Chem (2016). [link]
47. Measurements of monoclonal antibody self-association are correlated with complex biophysical properties, Mol Pharm (2016). [link]
47. Measurements of monoclonal antibody self-association are correlated with complex biophysical properties, Mol Pharm (2016). [link]
46. Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β reverses cognitive deficits produced by diet-induced obesity, Biochim Biophys Acta (2016). [link]
46. Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β reverses cognitive deficits produced by diet-induced obesity, Biochim Biophys Acta (2016). [link]
45. Design and optimization of anti-amyloid domain antibodies specific for Aβ and IAPP, J Biol Chem (2016). [link]
45. Design and optimization of anti-amyloid domain antibodies specific for Aβ and IAPP, J Biol Chem (2016). [link]
43. Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies, Protein Eng Des Sel (2015). [link]
43. Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies, Protein Eng Des Sel (2015). [link]
42. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy, Protein Eng Des Sel (2015). [link]
42. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy, Protein Eng Des Sel (2015). [link]
41. Comparison of human and bovine insulin amyloidogenesis under uniform shear, J Phys Chem B (2015). [link]
41. Comparison of human and bovine insulin amyloidogenesis under uniform shear, J Phys Chem B (2015). [link]
40. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies, mAbs (2015). [link]
40. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies, mAbs (2015). [link]
39. High-throughput assay for measuring monoclonal antibody self-association and aggregation in serum, Bioconjug Chem (2015). [link]
39. High-throughput assay for measuring monoclonal antibody self-association and aggregation in serum, Bioconjug Chem (2015). [link]
38. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions, J Pharm Sci (2014). [link]
38. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions, J Pharm Sci (2014). [link]
37. Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy, Biotech Bioeng (2014). [link]
37. Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy, Biotech Bioeng (2014). [link]
36. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process, Expert Opin Drug Deliv (2014). [link]
36. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process, Expert Opin Drug Deliv (2014). [link]
35. Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold, Protein Eng Des Sel (2014). [link]
35. Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold, Protein Eng Des Sel (2014). [link]
34. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy, mAbs (2014). [link]
34. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy, mAbs (2014). [link]
32. Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones, Chem Biol (2013). [link]
32. Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones, Chem Biol (2013). [link]
29. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates, Mol Pharm (2013). [link]
29. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates, Mol Pharm (2013). [link]
28. Rational design of potent domain antibody inhibitors of amyloid fibril assembly, P Natl Acad Sci U S A (2012). [link]
28. Rational design of potent domain antibody inhibitors of amyloid fibril assembly, P Natl Acad Sci U S A (2012). [link]
27. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions, Protein Eng Des Sel (2012). [link]
27. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions, Protein Eng Des Sel (2012). [link]
26. Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity, J Biol Chem (2012). [link]
26. Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity, J Biol Chem (2012). [link]
25. Polyphenolic disaccharides endow proteins with unusual resistance to aggregation, Biotech Bioeng (2012). [link]
25. Polyphenolic disaccharides endow proteins with unusual resistance to aggregation, Biotech Bioeng (2012). [link]
23. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength, Mol Pharm (2012). [link]
23. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength, Mol Pharm (2012). [link]
22. Structure-based design of conformation- and sequence-specific antibodies against amyloid β, P Natl Acad Sci U S A (2012). [link]
22. Structure-based design of conformation- and sequence-specific antibodies against amyloid β, P Natl Acad Sci U S A (2012). [link]
21. Removal versus fragmentation of amyloid-forming precursors via membrane filtration, Biotech Bioeng (2012). [link]
21. Removal versus fragmentation of amyloid-forming precursors via membrane filtration, Biotech Bioeng (2012). [link]
20. High-throughput analysis of concentration-dependent antibody self-association, Biophys J (2011). [link]
20. High-throughput analysis of concentration-dependent antibody self-association, Biophys J (2011). [link]
19. Site-specific structural analysis of a yeast prion strain with species-specific seeding activity, Prion (2011). [link]
19. Site-specific structural analysis of a yeast prion strain with species-specific seeding activity, Prion (2011). [link]
18. Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β, ChemBioChem (2011). [link]
18. Polyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β, ChemBioChem (2011). [link]
17. Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions, Proteins (2011). [link]
17. Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions, Proteins (2011). [link]
16. Aromatic small molecules remodel toxic soluble oligomers of amyloid ß through three independent pathways, J Biol Chem (2011). [link]
16. Aromatic small molecules remodel toxic soluble oligomers of amyloid ß through three independent pathways, J Biol Chem (2011). [link]
15. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aß into off-pathway conformers, J Biol Chem (2010). [link]
15. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aß into off-pathway conformers, J Biol Chem (2010). [link]
14. Unraveling molecular interactions and structures of self-perpetuating prions and amyloids, Nat Struct Mol Biol (2009). [link]
14. Unraveling molecular interactions and structures of self-perpetuating prions and amyloids, Nat Struct Mol Biol (2009). [link]
13. Biospecific immobilization of proteins for rapid analysis of weak protein interactions using self-interaction nanoparticle spectroscopy, Biotechnol Bioeng (2009). [link]
13. Biospecific immobilization of proteins for rapid analysis of weak protein interactions using self-interaction nanoparticle spectroscopy, Biotechnol Bioeng (2009). [link]
12. Self-interaction nanoparticle spectroscopy: A nanoparticle-based protein interaction assay, J Am Chem Soc (2008). [link]
12. Self-interaction nanoparticle spectroscopy: A nanoparticle-based protein interaction assay, J Am Chem Soc (2008). [link]
10. Direct measurement of protein osmotic second virial cross coefficients by cross-interaction chromatography, Protein Sci (2004). [link]
10. Direct measurement of protein osmotic second virial cross coefficients by cross-interaction chromatography, Protein Sci (2004). [link]
9. Predictive crystallization of ribonuclease A via rapid screening of osmotic second virial coefficients, Proteins (2003). [link]
9. Predictive crystallization of ribonuclease A via rapid screening of osmotic second virial coefficients, Proteins (2003). [link]
8. Measurement of protein self-association as a guide to crystallization, Curr Opin Biotechnol (2003). [link]
8. Measurement of protein self-association as a guide to crystallization, Curr Opin Biotechnol (2003). [link]
7. Correlation of diafiltration sieving behavior of lysozyme-BSA mixtures with osmotic second virial cross coefficients, Biotechol Bioeng (2003). [link]
7. Correlation of diafiltration sieving behavior of lysozyme-BSA mixtures with osmotic second virial cross coefficients, Biotechol Bioeng (2003). [link]
6. Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography, Biophys J (2002). [link]
6. Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography, Biophys J (2002). [link]
5. Self-interaction chromatography: A novel screening method for rational protein crystallization, Acta Cryst D (2002). [link]
5. Self-interaction chromatography: A novel screening method for rational protein crystallization, Acta Cryst D (2002). [link]
4. On-line spectroscopic characterization of sodium cyanide with nanostructured gold SERS substrates, Appl Spectrosc (2002). [link]
4. On-line spectroscopic characterization of sodium cyanide with nanostructured gold SERS substrates, Appl Spectrosc (2002). [link]
3. Structured metallic films for optical and spectroscopic applications via colloidal crystal templating, Adv Mater (2001). [link]
3. Structured metallic films for optical and spectroscopic applications via colloidal crystal templating, Adv Mater (2001). [link]
2. Assembly of gold nanostructured films templated by colloidal crystals and use in surface-enhanced Raman spectroscopy, J Am Chem Soc (2000). [link]
2. Assembly of gold nanostructured films templated by colloidal crystals and use in surface-enhanced Raman spectroscopy, J Am Chem Soc (2000). [link]